Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11. Juli 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
08. Juli 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
28. Juni 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11. Juni 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
03. Juni 2024 16:02 ET
|
Rhythm Pharmaceuticals, Inc.
Rhythm presents first-ever hypothalamic obesity patient-reported experiences with hyperphagia and positive changes in energy and sleep at ENDO2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
03. Juni 2024 08:02 ET
|
Rhythm Pharmaceuticals, Inc.
RYTM CEO at David Meeker at Goldman Sachs Global Healthcare Conference June 10.
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
22. Mai 2024 04:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
09. Mai 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
07. Mai 2024 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6...
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
06. Mai 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo...